Narrative review / 2022
GLP-1 receptor agonists are effective for obesity and T2DM, but their therapeutic effects are not fully congruent with endogenous GLP-1 actions.
This review examines the physiological functions of GLP-1 and its development into pharmaceuticals for obesity and type 2 diabetes (T2DM). GLP-1 receptor agonists are highlighted as effective anti-obesity agents and recommended second-line therapies for T2DM, particularly for patients with increased cardiovascular risk. The author discusses proglucagon processing across tissues and notes that the relationship between endogenous GLP-1 actions and the clinical effects of agonists is far from congruent and generally poorly understood.
- Study type
- Narrative review
- Who was studied
- Patients with obesity and type 2 diabetes (T2DM)
- What was measured
- Physiological actions and therapeutic effects of GLP-1 receptor agonists
THE PAPER
Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?
Holst JJ. J Intern Med, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.